Welcome to Managing Myeloma. I am Dr. Sagar Lonial. What we are going to talk about in this installment is that the treatment landscape for multiple myeloma continues to expand with many new drugs and combinations. One of the important educational messages that comes out at ASH is the idea that early relapse is the new newly diagnosed myeloma. What I mean by that is our concepts have been to treat very aggressively early on, to try and maximize depth of response. What we have seen from phase 3 updates at this meeting is that patients who have good depth of response with MRD negativity or overall high response rates in CR rate in the early salvage setting actually have prolonged progression-free and overall survival. What this means is the idea of using sequential single agents as salvage is probably gone in myeloma. Triplets are the ruling approach for the day, even in early relapse, and this approach can result in longer PFS and overall survival. Thank you very much for viewing this activity.
View Accredited Highlights in Multiple Myeloma from ASH 2017 here.